When was HTG Molecular Diagnostics founded?

HTG Molecular Diagnostics was founded in 1997 and raised its 1st funding round 8 years after it was founded.

Where is HTG Molecular Diagnostics located?

HTG Molecular Diagnostics is headquartered in Tucson, United States. It is registered at 3430 E. Global Loop, Tucson, AZ 85706.

How many employees does HTG Molecular Diagnostics have?

As of Sep 30, 2026, the latest employee count at HTG Molecular Diagnostics is 28.

Is HTG Molecular Diagnostics a funded company?

HTG Molecular Diagnostics is a funded company, having raised a total of $50.7M across 19 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on May 04, 2005.

When was the latest funding round of HTG Molecular Diagnostics?

HTG Molecular Diagnostics' latest funding was a $***** Post IPO round on Jun 25, 2020, with participation from 1 investor.

What is the annual revenue of HTG Molecular Diagnostics?

Annual revenue of HTG Molecular Diagnostics is between $1M and $10M as on Dec 31, 2022

Where does HTG Molecular Diagnostics rank among its competitors?

HTG Molecular Diagnostics ranks 83rd amongst 398 active competitors, of which 134 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was GenSight Biologics, which secured $1.96M in Mar, 2026.

Who are the top competitors of HTG Molecular Diagnostics?

HTG Molecular Diagnostics' top competitors include MedGenome, Geneoscopy and Intellia Therapeutics. Among them, GenSight Biologics secured the most recent funding round in March, 2026.

HTG Molecular Diagnostics - 2026 Company Profile, Funding, Competitors & Financials

HTG Molecular Diagnostics is a public company based in Tucson (United States), founded in 1997. It operates as a Developer of diagnostics and targeted therapeutics across a variety of disease areas. HTG Molecular Diagnostics has raised $50.7M in funding from investors like SR One, Fletcher Spaght and Merck. The company has 398 active competitors, including 134 funded and 85 that have exited. Its top competitors include companies like MedGenome, Geneoscopy and Intellia Therapeutics.

Company Details

Developer of diagnostics and targeted therapeutics across a variety of disease areas. The company is a leading provider of molecular-based technology solutions for gene expression profiling, miRNA, siRNA, and mRNA measurement for translational medicine and diagnostic applications. Their automated HTG Edge platform is designed to quickly and simultaneously profile thousands of clinically relevant molecular targets from samples a fraction of the size required by current technologies. Also offers services (VERI/O Laboratory Services ) such as retrospective sample processing, pilot studies, custom assay development, disease-specific validation studies, and molecular profiling studies

Website: htgmolecular.com
Social
Email ID: *****@htgmolecular.com
Phone Number: +1 **********
Registered Address: 3430 E. Global Loop, Tucson, AZ 85706

Key Metrics

Founded Year

1997

Location

Tucson, United States

Stage

Public

Total Funding

$50.7M in 19 rounds

Latest Funding Round

Post IPO, Jun 25, 2020, $*****

Investors

SR One & 12 more

Ranked

83^rd among 398 active competitors

Annual Revenue

$1M - $10M as on Dec 31, 2022

Employee Count

28 as on Sep 30, 2026

Similar Companies

MedGenome & 547 more

Exit Details

Public

View HTG Molecular Diagnostics' full profile

HTG Molecular Diagnostics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
HTG MOLECULAR DIAGNOSTICS, INC CIN: 1169987 , United States, Active	Dec 13, 2000	$1M - $10M (As on Dec 31, 2022)	-	-
HTG MOLECULAR DIAGNOSTICS, INC. CIN: 860912294 , United States, Active	Dec 31, 1999	-	47 (As on Dec 31, 2022)	-

HTG Molecular Diagnostics got listed on May 08, 2015.

Click here to take a look at HTG Molecular Diagnostics's IPO in detail

HTG Molecular Diagnostics has raised a total funding of $50.7M over 19 rounds. Its first funding round was on May 04, 2005. Its latest funding round was a Post IPO round on Jun 25, 2020 for $*****. 1 investor participated in its latest round. HTG Molecular Diagnostics has 13 institutional investors.

Here is the list of recent funding rounds of HTG Molecular Diagnostics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 25, 2020	5335427	Post IPO	3787672	6541301	5832460	7150876
Sep 24, 2019	1647033	Post IPO	9585739	4416480	3177696	9855449
Jan 28, 2018	5001060	Post IPO	7599897	7062194	4013388	Alven & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of HTG Molecular Diagnostics's funding rounds and investors

HTG Molecular Diagnostics' employee count trend

HTG Molecular Diagnostics has 28 employees as of Sep 26. Here is HTG Molecular Diagnostics's employee count trend over the years:

Employee count trend for HTG Molecular Diagnostics

Uncover HTG Molecular Diagnostics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of HTG Molecular Diagnostics include MedGenome, Geneoscopy and Intellia Therapeutics. Here is the list of Top 10 competitors of HTG Molecular Diagnostics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	MedGenome 2013, Bengaluru (India), Series E	Provider of DNA sequencing, bioinformatics, and multiomics services	$264M	Novo Holdings, Peak XV Partners & 30 others	70/100
2nd	Geneoscopy 2015, St. Louis (United States), Series C	Developer of non-invasive biomarker tests for colorectal cancer	$219M	LightChain Capital, Cultivation Capital & 18 others	67/100
3rd	Intellia Therapeutics 2014, Cambridge (United States), Public	Developer of therapeutics based on CRISPR/Cas9 technology for multiple diseases	$85M	Atlas Venture, Orbimed & 10 others	66/100
4th	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Coatue & 19 others	66/100
5th	Deep Genomics 2014, Toronto (Canada), Series C	AI-powered platform for RNA biology to accelerate genetic therapy discovery	$238M	SoftBank Vision Fund, True Ventures & 16 others	62/100
6th	UniQure 1998, Amsterdam (Netherlands), Public	Developer of gene-based therapies for patients with genetic or acquired diseases	$111M	Gilde Healthcare, Advent Life Sciences & 11 others	62/100
7th	Personalis 2011, Menlo Park (United States), Acquired	Provider of genomic sequencing and diagnosis software for the healthcare industry	$87.3M	Abingworth, Lightspeed Venture Partners & 5 others	61/100
8th	GenSight Biologics 2011, Paris (France), Public	Developer of viral vector-based gene therapies for retinal neurodegenerative diseases	$76.6M	Perceptive Advisors, Fidelity Investments ... & 17 others	61/100
9th	Seres Therapeutics 2010, Cambridge (United States), Public	Developer of microbiome therapeutics to treat a wide range of diseases	$134M	Flagship Pioneering, Mayo Clinic Business Accelerator ... & 8 others	60/100
10th	Dicerna Pharmaceuticals 2007, Lexington (United States), Acquired	Developer of drugs by using RNA interference technology platform	$106M	RA Capital Management, Domain Associates ... & 18 others	60/100
83rd	HTG Molecular Diagnostics 1997, Tucson (United States), Public	Developer of diagnostics and targeted therapeutics across a variety of disease areas	$50.7M	Autonomy Ventures, Novo Holdings & 11 others	43/100